Nuclera is a US and UK-based biotechnology company driven by the mission to better human health by making proteins accessible. Nuclera is enabling life science researchers to obtain active proteins from DNA in 48 hours through its benchtop eProtein DiscoveryTM platform.
Website: https://www.nuclera.com
Contact: hello@nuclera.com
Watch our showcase video: https://www.nuclera.com/resource-library/video-intro-to-eprotein-discovery/
Website: https://www.nuclera.com
Contact: hello@nuclera.com
Watch our showcase video: https://www.nuclera.com/resource-library/video-intro-to-eprotein-discovery/
Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery. Our partners include Shire, AstraZeneca, MedImmune and Takeda. Our objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, depression, chronic insomnia, addiction, migraine and diabetes.